Evidence map›Paper›PMID 25122777›Full record

ArticleJournal of virology2014

Type I interferon protects mice from fatal neurotropic infection with Langat virus by systemic and local antiviral responses.

Elvira Weber, Katja Finsterbusch, Richard Lindquist, Sharmila Nair, Stefan Lienenklaus, Nelson O Gekara, Dirk Janik, Siegfried Weiss, Ulrich Kalinke, Anna K Överby and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 88 citations in OpenAlex.

  1. Article
  2. Langat Virus Biology and Infection.Reviews in medical virology · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. MITD1 is a brain-specific interferon-inducible factor that inhibits flavivirus replication.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Impact of Tick-BorneInternational journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. West Nile virus unmasked: from gene variability to future challenges.Frontiers in cellular and infection microbiology · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Elvira WeberDepartment of Clinical Microbiology, Virology, Umeå University, Umeå, Sweden.
Katja FinsterbuschInnate Immunity and Infection, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Richard LindquistDepartment of Clinical Microbiology, Virology, Umeå University, Umeå, Sweden.
Sharmila NairInnate Immunity and Infection, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Stefan LienenklausDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Nelson O GekaraDepartment of Molecular Biology, Umeå University, Umeå, Sweden.
Dirk JanikInstitute of Pathology, Helmholtz Center Munich, Neuherberg, Germany.
Siegfried WeissDepartment of Molecular Immunology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
Ulrich KalinkeInstitute for Experimental Infection Research, TWINCORE, Hannover, Germany.
Anna K ÖverbyDepartment of Clinical Microbiology, Virology, Umeå University, Umeå, Sweden anna.overby@climi.umu.se andrea.kroeger@helmholtz-hzi.de.
Andrea KrögerInnate Immunity and Infection, Helmholtz Centre for Infection Research, Braunschweig, Germany anna.overby@climi.umu.se andrea.kroeger@helmholtz-hzi.de.
Helmholtz Centre for Infection Research · DEUmeå University · SECenter for Experimental and Clinical Infection Research · DEHelmholtz Zentrum München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledVector-borne flaviviruses, such as tick-borne encephalitis virus (TBEV), West Nile virus, and dengue virus, cause millions of infections in humans. TBEV causes a broad range of pathological symptoms, ranging from meningitis to severe encephalitis or even hemorrhagic fever, with high mortality. Despite the availability of an effective vaccine, the incidence of TBEV infections is increasing. Not much is known about the role of the innate immune system in the control of TBEV infections. Here, we show that the type I interferon (IFN) system is essential for protection against TBEV and Langat virus (LGTV) in mice. In the absence of a functional IFN system, mice rapidly develop neurological symptoms and succumb to LGTV and TBEV infections. Type I IFN system deficiency results in severe neuroinflammation in LGTV-infected mice, characterized by breakdown of the blood-brain barrier and infiltration of macrophages into the central nervous system (CNS). Using mice with tissue-specific IFN receptor deletions, we show that coordinated activation of the type I IFN system in peripheral tissues as well as in the CNS is indispensable for viral control and protection against virus induced inflammation and fatal encephalitis. IMPORTANCE: The type I interferon (IFN) system is important to control viral infections; however, the interactions between tick-borne encephalitis virus (TBEV) and the type I IFN system are poorly characterized. TBEV causes severe infections in humans that are characterized by fever and debilitating encephalitis, which can progress to chronic illness or death. No treatment options are available. An improved understanding of antiviral innate immune responses is pivotal for the development of effective therapeutics. We show that type I IFN, an effector molecule of the innate immune system, is responsible for the extended survival of TBEV and Langat virus (LGTV), an attenuated member of the TBE serogroup. IFN production and signaling appeared to be essential in two different phases during infection. The first phase is in the periphery, by reducing systemic LGTV replication and spreading into the central nervous system (CNS). In the second phase, the local IFN response in the CNS prevents virus-induced inflammation and the development of encephalitis.

Indexed as

AnimalsEncephalitis, Tick-BorneEncephalitis Viruses, Tick-BorneInterferon Type IMice, Inbred C57BLMice, KnockoutReceptors, InterferonSurvival AnalysisInterferon Type IReceptors, Interferon

Identifiers

PMID25122777
PMCPMC4248936
OpenAlexW2018247663

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.